Health Economics›Neuroblastoma›Intermediate-risk all lines of therapy

Intermediate-risk all lines of therapy

Neuroblastoma · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
COG ANBL0531 group	—	R 27 843	21d	—	—	~5	~R 83 358 indirect	—
COG A3961 protocol Variant #01	—	R 4 972	21d	—	—	~5	~R 24 467 indirect	—

2 of 2 regimens shown